Results 21 to 30 of about 81,306 (284)

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction [PDF]

, 2013
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric ...
Klautke, Gunther, Galle, Peter R., Brenner, Baruch, Arnold, Dirk, Roessler, Hans-Peter, Thomaidis, Thomas, Schimanski, Carl Christoph, Schmidberger, Heinz, Rödel, Claus, Gockel, Ines, Möhler, Markus, Trarbach, Tanja, Lang, Hauke   +12 more
core   +1 more source

Evidence for Two Modes of Synergistic Induction of Apoptosis by Mapatumumab and Oxaliplatin in Combination with Hyperthermia in Human Colon Cancer Cells [PDF]

, 2013
Colorectal cancer is the third leading cause of cancer-related mortality in the world-- the main cause of death from colorectal cancer is hepatic metastases, which can be treated with isolated hepatic perfusion (IHP).
Yong J. Lee, Yong J. Lee (297943), Song, X, Lee, YJ, Seog-Young Kim, Song Xinxin, Xinxin Song, Kim Seog-Young, Yong J Lee, Xinxin Song (297942), Song, Xinxin, Lee Yong J., Kim, Seog-Young, Seog-Young Kim (297940), Kim, SY, Calogero, Raffaele A, Lee, Yong J.   +16 more
core   +2 more sources

Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia [PDF]

, 2007
Background: Irinotecan-based second-line chemotherapy of metastatic colorectal cancer (CRC) is effective, it might, however, be contraindicated in cases of severe liver dysfunction due to advanced liver metastases.
Moosmann, Nicolas, Schulz, Christoph, Laessig, Dorit, Michaely, Henrik Jakob, Heinemann, Volker   +4 more
core   +1 more source

Goshajinkigan, a Traditional Japanese Medicine, Prevents Oxaliplatin-Induced Acute Peripheral Neuropathy by Suppressing Functional Alteration of TRP Channels in Rat

Journal of Pharmacological Sciences, 2014
.: The acute peripheral neuropathy induced by oxaliplatin treatment occurs very frequently and is aggravated by exposure to cold. Goshajinkigan (GJG), a traditional Japanese (kampo) medicine, was recently shown to be effective against oxaliplatin-induced
Keita Mizuno, Toru Kono, Yasuyuki Suzuki, Chika Miyagi, Yuji Omiya, Kanako Miyano, Yoshio Kase, Yasuhito Uezono   +7 more
doaj   +1 more source

KIAA1199 promotes oxaliplatin resistance and epithelial mesenchymal transition of colorectal cancer via protein O-GlcNAcylation

Translational Oncology, 2023
Oxaliplatin is a commonly used platinum drug for colorectal cancer (CRC). However, the treatment of CRC by oxaliplatin usually fails because of drug resistance, which results in a huge challenge in the therapy of CRC.
Qingling Hua, Yuanyuan Lu, Dingxiang Wang, Jie Da, Wanren Peng, Guoping Sun, Kangsheng Gu, Hua Wang, Yanzhe Zhu   +8 more
doaj   +1 more source

Regrowth resistance: low-level platinum resistance mediated by rapid recovery from platinum-induced cell-cycle arrest [PDF]

, 2009
The H69CIS200 and H69OX400 cell lines are novel models of low-level platinum drug resistance developed from H69 human small cell lung cancer cells with eight 4-day treatments of 200 ng/ml cisplatin or 400 ng/ml oxaliplatin respectively. A recovery period
Ross Davey, Davey, Ross, Britta Stordal, Stordal, Britta   +3 more
core   +2 more sources

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial [PDF]

, 2006
Oral capecitabine (Xeloda^®) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer.
F Coxon, T S Maughan, Douillard, J.Y., Lesniewski-Kmak, K, Bertetto, O., Jelic, S., Maughan, T.S., Dufour, A., J-Y Douillard, Johnston, P G, C Twelves, Díaz-Rubio, E., Cassidy, J, Twelves, C., Jelic, S, P G Johnston, Figer, A, G Fountzilas, W Scheithauer, Patel, K K, Malzyner, A, Fountzilas, G., K Lesniewski-Kmak, A Malzyner, Maughan, TS, Bustová, I, Cowell, W., Garrison, L.P., Twelves, C, Díaz-Rubio, E, O Bertetto, W Cowell, Beham, A, S Jelic, Maughan, Tim, Dufour, P, J J McKendrick, Scheithauer, W., Douillard, JY, Cowell, W, Lesniewski-Kmak, K., Garrison, L P, Bustová, I., Beham, A., Fountzilas, G, Johnston, PG, A Beham, Garrison, LP, K K Patel, Patel, KK, I Bustová, Cassidy, J., McKendrick, J.J., Bertetto, O, L P Garrison, Coxon, F., Patel, K.K., Douillard, J-Y, P Dufour, A Figer, Johnston, P.G., Scheithauer, W, Coxon, F, Maughan, T S, McKendrick, JJ, J Cassidy, E Díaz-Rubio, McKendrick, J J, Malzyner, A., Figer, A.   +69 more
core   +1 more source

Advances in the Management of Oxaliplatin-Induced Neuropathy: Focus on Glutamine and Using Pharmacogenomics to Predict the Effectiveness of Opioid Drugs

Journal of Cancer Research and Practice, 2014
One form of neurotoxicity is the principal and dose-limiting toxicity of oxaliplatin. It has been observed that the incidence of oxaliplatin-induced severe neurotoxicity has varied from 12% to 18% in different clinical trials.
Wei-Shu Wang
doaj   +1 more source

Oxaliplatin-Associated Amaurosis Fugax [PDF]

, 2021
Oxaliplatin-associated amaurosis fugax has not been reported, and its clinical course and treatment remain largely unclear. A 70-year-old man with advanced gastric cancer was treated with the SOX regimen.
Momoko Tsuda, Mototsugu Kato, Kimitoshi Kubo, Masayuki Higashino, Ryosuke Watanabe, Noriko Kimura   +5 more
core   +1 more source

Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions

Allergology International
Background: Oxaliplatin is commonly used to treat gastrointestinal malignancies. However, its applications are limited due to potential adverse drug reactions (ADRs), particularly severe anaphylactic shock.
Hung-Chih Hsu, Wen-Hung Chung, Yung-Chang Lin, Tsai-Sheng Yang, John Wen-Cheng Chang, Chia-Hsun Hsieh, Shuen-Iu Hung, Chun-Wei Lu, Jen-Shi Chen, Wen-Chi Chou, Chuang-Wei Wang   +10 more
doaj   +1 more source